Unlocking the Biological Potential of LERK-3: Structure, Function and Translational Applications

Concept

LERK-3, also known as Ephrin-A3 (EFNA3), is a glycosylphosphatidylinositol (GPI)-anchored membrane protein belonging to the Ephrin ligand family. It acts as a critical signaling molecule that mediates bidirectional cell communication with Eph receptors, governing diverse biological processes ranging from tissue development to disease progression. Its recombinant form, a core product of ANT BIO PTE. LTD. sub-brand UA, serves as an essential research tool for exploring the Eph/Ephrin signaling axis.

Research Frontier

Eph/Ephrin signaling is a hot topic in developmental biology, oncology, and regenerative medicine. As a key ligand in this axis, LERK-3 has emerged as a research focal point due to its unique bidirectional signaling capability and multifaceted roles in neurodevelopment, angiogenesis, tumor metastasis, and immune regulation. Recent advances in protein engineering, structural biology, and disease modeling have deepened our understanding of LERK-3’s structure-function relationship and unlocked its potential as a therapeutic target.

Research Significance

LERK-3 plays irreplaceable roles in physiological and pathological processes:

· Developmental regulation: Guides neural cell migration and vascular formation, shaping tissue architecture.

· Disease intervention: Acts as a key driver of tumor metastasis and a promising target for spinal cord injury repair and autoimmune disease treatment.

· Biomedical innovation: Its recombinant protein and derived molecules offer novel tools for precision therapy and disease mechanism research.

Elucidating LERK-3’s biological functions and regulatory mechanisms not only advances basic life science research but also provides critical theoretical support for developing targeted drugs and regenerative medicine strategies.

Mechanisms and Product Applications

1. Structural Characteristics of LERK-3 Recombinant Protein

Produced via the HEK293 expression system with a C-terminal His-tag for easy purification, LERK-3 recombinant protein features four core structural modules:

· Signal peptide: Facilitates membrane localization and protein secretion.

· Ephrin domain (~20 kDa): Highly conserved, mediates specific binding to Eph receptors (e.g., EPHA8).

· Cysteine-rich GPI anchoring domain: Ensures stable attachment to the cell membrane.

· Flexible linker region: Enables conformational changes to adapt to different Eph receptor subtypes.

2. Core Biological Functions: Bidirectional Signaling

LERK-3 uniquely triggers bidirectional signaling by interacting with Eph receptors:

· Forward signaling: Activates Eph receptors, triggering Rho GTPase-mediated cytoskeletal remodeling to regulate neuronal axon guidance and endothelial cell migration.

· Reverse signaling: Recruits adaptor proteins (e.g., PDZ domain proteins) via its intracellular region, activating Src kinase or PI3K/AKT pathways to modulate cell adhesion and survival.

3. Key Physiological and Pathological Roles

· Neurodevelopment: Mediates repulsive signals to guide neural crest cell migration, forming the dorsal spinal cord neuronal network.

· Angiogenesis: Exerts dose-dependent regulation—low concentrations promote endothelial proliferation, while high concentrations induce apoptosis, controlling pathological angiogenesis.

· Tumor progression: Overexpressed in glioblastoma and breast cancer, it drives tumor cell detachment and metastasis. Soluble LERK-3 recombinant protein blocks Eph receptor activation, reducing melanoma lung metastasis by 42% in preclinical models.

· Regenerative medicine: Hydrogel-encapsulated LERK-3 guides neuronal synapse regeneration, improving motor function recovery by 42% in spinal cord injury models.

· Autoimmune diseases: Inhibits Th17 cell differentiation, reducing joint inflammation scores by 57% in rheumatoid arthritis models.

4. Research Challenges and Solutions

Current research faces three main bottlenecks:

1. Unclear spatiotemporal regulation of bidirectional signaling.

2. Short in vivo half-life (~2.3 hours) of recombinant proteins.

3. Functional redundancy among Ephrin family members.

Breakthrough solutions include:

· Nanobody engineering: High-affinity anti-LERK-3 nanobodies (KD=0.8 nM) extend half-life to 72 hours with superior tissue penetration.

· Gene editing: CRISPR-Cas9 knockout models enable precise functional analysis.

· Protein engineering: Directed evolution generates long-acting, tissue-targeted recombinant proteins.

5. Product Application of ANT BIO PTE. LTD.

As a core product of ANT BIO PTE. LTD. sub-brand UA (focused on recombinant proteins), LERK-3 recombinant protein is optimized for high purity, stability, and biological activity, supporting:

· Basic research on Eph/Ephrin signaling mechanisms.

· Preclinical evaluation of tumor metastasis and regenerative medicine therapies.

· Development of anti-LERK-3 antibodies and targeted drugs.

Brand Mission

ANT BIO PTE. LTD. is committed to driving life science innovation by providing high-quality recombinant proteins, antibodies, and research reagents. With three specialized sub-brands—Absin (general reagents/kits), Starter (antibodies), and UA (recombinant proteins)—we deliver reliable, platform-validated products to address key research challenges in developmental biology, oncology, and regenerative medicine. We strive to empower global researchers to uncover biological mysteries and accelerate translational medicine breakthroughs.

Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.